Lexicon Pharma (LXRX) Tops Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.34 -2.5%
EPS Growth %: -600.0%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
CRMT, FOMI, FLES, More
EPS Growth %: -600.0%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
CRMT, FOMI, FLES, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.37), $0.04 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $20.1 million versus the consensus estimate of $12.36 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump discloses over $1.4 billion in crypto income in 2025 filing
- General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance
- Biogen expects $164M R&D charge to hit Q2 2026 earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
